Today, in Europe, there are inequalities in access to care and treatment for dementia, according to a report produced by the organization Alzheimer Europe. In the case of Spain, the document places our country among 18 states without “sufficient availability” of health services to treat dementia. The same thing happens in similar countries like France, Hungary, the United Kingdom, and Italy. In contrast, Denmark, Luxembourg, and Norway report that at least 50% of their services in this area are adequate.
To reach this conclusion, the authors of the document introduced ten health services with a positive impact on the quality of life of people with dementia and their caregivers that should be present in European health systems. These are: home adaptation, the so-called “Alzheimer’s cafes,” coordination and case management, training for caregivers, day hospitals, home care, relief from home care, support for groups of caregivers, support for associations of patients with dementia, and home nursing care.
On the other hand, one of the points of the report in Spain is the protection of legal rights for people with dementia. In this sense, the authors recognize that there is an “increasing number” of countries that follow the five recommendations given by Alzheimer Europe: Austria, Croatia, the Czech Republic, Denmark, France, Germany, Iceland, Ireland, Israel, Italy, Jersey, the Netherlands, Norway, Portugal, Slovenia, Spain, Sweden, and the United Kingdom. But they “suspended” Bulgaria, North Macedonia, Poland, and Romania because they did not get any points in this category.
Among the countries that have made further advances in clinical research on dementia Located in Spain. Specifically, the report shows that our country, along with the Netherlands and the United Kingdom, is in second place, with seven active clinical trials. while France stands out as the only country where people with dementia were able to participate in eight of the ten phase III clinical trials studied for the report. On the opposite side, with no clinical research in this area, are Armenia, Lithuania, Luxembourg, Malta, and North Macedonia.
Only Greece, Ireland, Slovakia, Sweden, and the United Kingdom have implemented a working group or strategy to prepare for the introduction of new anti-amyloid treatments for Alzheimer’s disease.
Finally, the authors note that while Europe is waiting for approval from the European Medicines Agency (EMA) for a new anti-amyloid treatment for Alzheimer’s disease, only Greece, Ireland, Slovakia, Sweden, and the United Kingdom have implemented a working group or strategy to prepare for the introduction of these new treatments.
For the executive director of Alzheimer Europe, Jean Georges, “It is heartening to see that many countries have managed to improve the situation of people with dementia, as well as their carers.“. However, Georges warns that this development is not the same as in other European regions.
“Our report shows that there are still clear divisions between East and West and Northern Europe, where scores are higher,” assured the executive director. Therefore, he insisted that “it is time for all European countries, and especially those in Eastern Europe, to recognize dementia as a national priority and develop national dementia strategies.“.